A new batch of chemicals used in the manufacture of Vrp and VrP is making its way to pharmacies and health centres across the country, with the Federal Government promising a more robust response.
Mr Scott, the federal health minister, says there will be “a more robust approach to dealing with the issue of VRP”.
“The Department of Health is committed to working closely with our pharmaceutical supply chain partners to provide a more comprehensive and targeted response to VRP concerns, as well as the concerns of our medical communities, which are currently under the threat of VRPs,” Mr Scott said.
Vrps are the chemicals in Vrpa’s syringes that cause vomiting, diarrhoea, nausea and vomiting.
In a statement, Mr Scott says the Government will provide greater resources for the VRP industry, including “additional support for the industry, support to ensure its compliance and compliance monitoring”.
“We are working to ensure that the industry continues to meet their requirements and is able to continue to operate safely and effectively in Australia,” he said.
The Government has also introduced new regulations, including the requirement for a pharmacist to be present during the dispensing of any VRP product. “
This includes ensuring the industry is appropriately equipped and trained and we are providing more support for those who need it.”
The Government has also introduced new regulations, including the requirement for a pharmacist to be present during the dispensing of any VRP product.
Mr Crouch, chief executive of Vripta, said the Government had not yet made any decision on what level of protection the company would need to give its VRP customers.
“We’re currently in discussions with the pharmaceutical industry and will have a further comment to make on that in due course,” he told ABC Radio National’s RN Breakfast.
The Federal Government has set up a helpline for patients, pharmacists and healthcare professionals to discuss the concerns surrounding VRP.
“You can call the helplines directly to discuss your concerns, and we will make sure that there is a clear and robust response to these issues,” Mr Copley said.
”We know that many patients are not able to access the full range of care, particularly with VRP products.
The best way to ensure patients are getting the quality of care they need is to ensure a level of safety and efficacy that meets their needs.